MicuRx is a biopharmaceutical company focusing on novel therapeutics for infectious diseases. With global independent intellectual property and competitiveness, we are committed to the discovery, development, and commercialization of innovative drugs for unmet medical needs. Since the company was founded in 2007, MicuRx has adhered to the principle of “Better therapy through superior medicine", focusing on the increasingly serious problem of global antimicrobial resistance. With the core competitiveness of solving clinical problems and differentiated innovation, our goal is to provide more effective and safer therapeutic options for patients suffering the most common and serious drug-resistant bacterial infections.
Founded by Dr. Zhengyu Yuan and Dr. Mikhail F. Gordeev, and led by an international core scientific and management team, MicuRx has established R&D centers in China and the US. Key members of our scientific department have rich experience in international innovative drug development and management, and have led or participated in the development of a number of marketed antimicrobial new drugs. MicuRx insists on the self-development strategy, concentrates in specialized fields, and has established an integrated antibacterial new drug R&D system covering early design and screening of innovative drugs, preclinical evaluation, global clinical development, manufacturing management, and regulatory affairs. Following international practice and standards, the company succeeds with the China-US parallel development strategy.
MicuRx has built a robust pipeline of 6 independently developed innovative drug candidates, focusing on new antibiotics against multidrug-resistant “super-bacteria” and has expanded into the field of nephrology. MicuRx has successfully completed 9 Phase 1, 3 Phase 2, and 1 Phase 3 clinical trials globally, and 2 Phase 1 clinical trials are in progress. The application for the company’s first category 1 innovative drug, contezolid, was accepted by the China National Medical Products Administration (NMPA) in December 2019 and was granted priority review. The NMPA approved the new drug application for contezolid for the treatment of complicated skin and soft tissue infection on June 1, 2021.
The development of the company's core products has been strongly supported by both the Chinese and US governments. In China, the three core products of MicuRx have been supported by the National Major Scientific and Technological Special Project for “Significant New Drugs Development”. In particular, the development of contezolid is supported during 11th, 12th, and 13th five-year periods. Contezolid and MRX-4 have been certified as Qualified Infectious Disease Products (QIDP) by the US FDA.
In order to realize and expand the clinical value of our products, MicuRx also established a professional commercialization team covering sales, marketing, medical, business, operational efficiency, government affairs, and other functions. With integrated, well-experienced management, technical, and commercial teams, MicuRx is dedicated to addressing unmet global clinical needs and promoting innovation in drug development.